Pharmacotherapy options for cataplexy

Bibliography

• Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 2007;369(9560):499-511
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Montplaisir J, Molinari N, Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001;57(11):2029-33
   PubMed Web of Science ®Google Scholar
• Peyron C, Faraco J, Rogers W, A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nature Med 2000;6(9):991-7
   PubMed Web of Science ®Google Scholar
• Billiard M, Bassetti C, Dauvilliers Y, EFNS guidelines on management of narcolepsy. Eur J Neurol 2006;13(10):1035-48
   PubMed Web of Science ®Google Scholar
• Plazzi G, Pizza F, Palaia V, Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. Brain 2011;134(12):3480-92
   Google Scholar
• Luppi PH, Clément O, Sapin E, The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorder. Sleep Med Rev 2011;15(3):153-63
   PubMed Web of Science ®Google Scholar
• Peever J. Control of motoneuron function and muscle tone during REM sleep, REM sleep behavior disorder and cataplexy/narcolepsy. Arch Ital Biol 2011;149(4):454-66
   PubMed Web of Science ®Google Scholar
• Mignot E, Nishino S, Sharp LH, Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems. J Neurosci 1993;13(3):1057-64
   PubMed Web of Science ®Google Scholar
• Burgess CR, Tse G, Gillis L, Peever JH. Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy. Sleep 2010;33(10):1295-304
   PubMed Web of Science ®Google Scholar
• Reid MS, Tafti M, Nishino S, Cholinergic regulation of cataplexy in canine narcolepsy in the pontine reticular formation is mediated by M2 muscarinic receptors. Sleep 1994;17(5):424-35
   PubMed Web of Science ®Google Scholar
• Nishino S, Tafti M, Reid MS, Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of canine narcolepsy. J Neurosci 1995;15(7):4806-14
   PubMed Web of Science ®Google Scholar
• Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997;52(1):27-78
   PubMed Web of Science ®Google Scholar
• Wu MF, John J, Boehmer L, Activity of dorsal raphe cells across the sleep–waking cycle and during cataplexy in narcoleptic dogs. J Physiol 2004;554(1):202-15
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Baumann C, Carlander B, CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 2003;74(12):1667-73
   PubMed Web of Science ®Google Scholar
• Hara J, Beuckmann CT, Nambu T, Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001;30(2):345-54
   PubMed Web of Science ®Google Scholar
• Chemelli RM, Willie JT, Sinton CM, Narcolepsy in orexin Knockout Mice: molecular Genetics of Sleep Regulation. Cell 1999;98(4):437-51
   PubMed Web of Science ®Google Scholar
• Willie JT, Chemelli RM, Sinton CM, Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 2003;38(5):715-30
   PubMed Web of Science ®Google Scholar
• Poryazova R, Siccoli M, Werth E, Bassetti CL. Unusually prolonged rebound cataplexy after withdrawal of fluoxetine. Neurology 2005;65(6):967-8
   PubMed Web of Science ®Google Scholar
• Akimoto H, Honda Y, Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Syst 1960;21:704
   PubMedGoogle Scholar
• Hishikawa Y, Ida H, Nakai K, Kaneko Z. Treatment of narcolepsy with imipramine (tofranil) and desmethylimipramine (pertofran). J Neurol Sci 1966;3(5):453-61
   PubMed Web of Science ®Google Scholar
• Linnoila M, Simpson D, Skinner T. Characteristics of therapeutic response to imipramine in cataplectic men. Am J Psychiatry 1980;137(2):237-8
   PubMed Web of Science ®Google Scholar
• Attacks S. Protriptyline: an effective agent in the treatment of the narcolepsy-cataplexy syndrome and hypersomnia. Am J Psychiatry 1977;134(2):183-5
   PubMed Web of Science ®Google Scholar
• Schachter M, Parkes J. Fluvoxamine and clomipramine in the treatment of cataplexy. J Neurol Neurosurg Psychiatry 1980;43(2):171-4
   PubMed Web of Science ®Google Scholar
• Shapiro WR. Treatment of cataplexy with clomipramine. Arch Neurol 1975;32(10):653-6
   PubMedGoogle Scholar
• Guilleminault C, Raynal D, Takahashi S, Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand 1976;54(1):71-87
   PubMed Web of Science ®Google Scholar
• Parkes J, Schachter M. Clomipramine and clonazepam in cataplexy. Lancet 1979;2(8151):1085-6
   PubMed Web of Science ®Google Scholar
• Bental E, Lavie P, Sharf B, Severe hypermotility during sleep in treatment of cataplexy with clomipramine. Isr J Med Sci 1979;15(7):607-9
   PubMedGoogle Scholar
• Martinez-Rodriguez J, Iranzo A, Santamaria J, Status cataplecticus induced by abrupt withdrawal of clomipramine. Neurologia 2002;17(2):113-16
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ. How do antidepressants work. In: Davis JM, Mass JW, editors. The affective disorders. American Psychiatric Press; Wachington, DC: 1983. p. 243-60
   Google Scholar
• Henry G, Hart R, Kwentus J, Sicola M. Effects of protryptiline on vigilance and information processing in narcolepsy. Psychopharmacology (Berl) 1988;95:109-12
   PubMed Web of Science ®Google Scholar
• Wyatt RJ, Fram DH, Buchbinder R, Snyder F. Treatment of intractable narcolepsy with a monoamine oxidase inhibitor. N Engl J Med 1971;285(18):987-91
   PubMed Web of Science ®Google Scholar
• Hublin C, Partinen M, Heinonen E, Selegiline in the treatment of narcolepsy. Neurology 1994;44(11):2095
   PubMed Web of Science ®Google Scholar
• Mayer G, Meier KE, Selegeline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol 1995;18(4):306-19
   PubMed Web of Science ®Google Scholar
• Hohagen F, Mayer G, Menche A, Treatment of narcolepsy-cataplexy syndrome with the new selective and reversible MAO-A inhibitor brofaromine—a pilot study. J Sleep Res 1993;2(4):250-6
   PubMed Web of Science ®Google Scholar
• Langdon N, Shindler J, Parkes J, Bandak S. Fluoxetine in the treatment of cataplexy. Sleep 1986;9(2):371-3
   PubMed Web of Science ®Google Scholar
• Frey J, Darbonne C. Fluoxetine suppresses human cataplexy A pilot study. Neurology 1994;44(4):707
   PubMed Web of Science ®Google Scholar
• Schrader H, Kayed K, Markset AC, Treidene H. The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo. Acta Neurol Scand 1986;74(4):297-303
   PubMed Web of Science ®Google Scholar
• Godbout R, Montplaisir J. The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness of narcoleptic patients. Clin Neuropharmacol 1986;9(1):46-51
   PubMed Web of Science ®Google Scholar
• Thirumalai SS, Shubin RA. The use of citalopram in resistant cataplexy. Sleep Med 2000;1(4):313-16
   PubMed Web of Science ®Google Scholar
• Sonka K, Kemlink D, Pretl M, Cataplexy treated with escitalopram–clinical experience. Neuro Endocrinol Lett 2006;27(1-2):174-6
   PubMed Web of Science ®Google Scholar
• Smith M, Parkes J, Dahlitz M. Venlafaxine in the treatment of the narcoleptic syndrome. J Sleep Res 1996;5(Suppl 1):217
   Google Scholar
• Plazzi G, Montagna P, Provini F, Treatment of narcolepsy with cataplexy. Lancet 2007;369(9567):1081
   PubMedGoogle Scholar
• Moller LR, Ostergaard JR. Treatment with venlafaxine in six cases of children with narcolepsy and with cataplexy and hypnagogic hallucinations. J Child Adolesc Psychopharmacol 2009;19(2):197-201
   PubMed Web of Science ®Google Scholar
• Aran A, Einen M, Lin L, Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: a retrospective study of 51 children. Sleep 2010;33(11):1457-64
   PubMed Web of Science ®Google Scholar
• Izzi F, Placidi F, Marciani M, Effective treatment of narcolepsy–cataplexy with duloxetine: a report of three cases. Sleep Med 2009;10(1):153-4
   PubMed Web of Science ®Google Scholar
• Sagawa Y, Inoue Y, Kaneko Y, The anticataplectic effect of milnacipran, a new SNRI, on canine and human narcolepsy. Sleep Biol Rhythms 2007;5(s1):A78
   Google Scholar
• Guilleminault C, Mancuso J, Salva M, Viloxazine hydrochloride in narcolepsy: a preliminary report. Sleep 1986;9(1 Pt 2):275-9
   PubMed Web of Science ®Google Scholar
• Larrosa O, de la Llave Y, Bario S, Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep 2001;24(3):282-5
   PubMed Web of Science ®Google Scholar
• Niederhofer H. Atomoxetine also effective in patients suffering from narcolepsy? Sleep 2005;28(9):1189
   PubMed Web of Science ®Google Scholar
• Goksan B, Mercan S, Karamustafalioglu O. Bupropion is effective in depression in narcolepsy. Int J Psychiatry Clin Pract 2005;9(4):289-91
   PubMed Web of Science ®Google Scholar
• Pistis M, Muntoni AL, Pillolla G, γ-Hydroxybutyric acid (GHB) and the mesoaccumbens reward circuit: evidence for GABAB receptor-mediated effects. Neuroscience 2005;131(2):465-74
   PubMed Web of Science ®Google Scholar
• Broughton R, Mamelak M. Effects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy-cataplexy. Can J Neurol Sci 1980;7(1):23-31
   PubMed Web of Science ®Google Scholar
• Boscolo-Berto R, Viel G, Montagnese S, Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev 2012;16(5):431-43
   PubMed Web of Science ®Google Scholar
• Lammers G, Arends J, Declerck A, Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep 1993;16(3):216-20
   PubMed Web of Science ®Google Scholar
• Scrima L, Hartman PG, Johnson FH, Charles Hiller F. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol psychiatry 1989;26(4):331-43
   PubMed Web of Science ®Google Scholar
• Group UXMS. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25(1):42-9
   PubMed Web of Science ®Google Scholar
• Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006;29(7):939-46
   PubMed Web of Science ®Google Scholar
• Mignot E, Renaud A, Nishino S, Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology (Berl) 1993;113(1):76-82
   PubMed Web of Science ®Google Scholar
• Nittur N, Konofal E, Dauvilliers Y, Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review. Sleep Med 2013;14(1):30-6
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Carlander B, Touchon J, Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 2004;56(6):905-8
   PubMed Web of Science ®Google Scholar
• Lecendreux M, Maret S, Bassetti C, Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 2003;12(4):347-8
   PubMed Web of Science ®Google Scholar
• Plazzi G, Poli F, Franceschini C, Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J Neurol 2008;255(10):1549-54
   PubMed Web of Science ®Google Scholar
• Fronczek R, Verschuuren J, Lammers GJ. Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy. J Neurol 2007;254(11):1607-8
   PubMed Web of Science ®Google Scholar
• Chen W, Black J, Call P, Mignot E. Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Ann Neurol 2005;58(3):489-90
   PubMed Web of Science ®Google Scholar
• Pincherle A, Villani F, Ferini Strambi L, Immunoadsorption for the treatment of narcolepsy with cataplexy. Neurol Sci 2008;29(6):499-500
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Abril B, Mas E, Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. Neurology 2009;73(16):1333-4
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y. Follow-up of four narcolepsy patients treated with intravenous immunoglobulins. Ann Neurol 2006;60(1):153
   PubMed Web of Science ®Google Scholar
• Donjacour CEHM, Lammers GJ. A remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexy. J Sleep Res 2012;21(4):479-80
   PubMed Web of Science ®Google Scholar
• Lin JS, Dauvilliers Y, Arnulf I, An inverse agonist of the histamine H (3) receptor improves wakefulness in narcolepsy: studies in orexin-/-mice and patients. Neurobiol Dis 2008;30(1):74-83
   PubMed Web of Science ®Google Scholar
• Deadwyler SA, Porrino L, Siegel JM, Hampson RE. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 2007;27(52):14239-47
   PubMed Web of Science ®Google Scholar
• Baier PC, Weinhold SL, Huth V, Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1). Brain 2008;131(10):2734-41
   PubMedGoogle Scholar